Alvotech enters into commercialization agreement with
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia,...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-06, 16:08
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-02, 20:05
Surface Oncology to Participate in the 2023 Guggenheim
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-02, 02:42
Premiere Synthetic Biology Event on Track for Record
SynBioBeta Global Synthetic Biology Conference Registration Open SynBioBeta announces event dates, keynotes, sponsors, and location SAN FRANCISCO,...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-01-31, 21:19
Envision Pharma Group Hires Leading Industry Executives
PHILADELPHIA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Envision Pharma Group (Envision) today announced the appointment of two senior executives while further...
